Home Infusion Therapy Insurance Claim Denied? How to Appeal

Home infusion therapy — receiving intravenous medications at home rather than in a hospital or infusion center — can dramatically improve quality of life for patients with chronic conditions requiring long-term IV therapy. It is also consistently less expensive than facility-based infusion, making clinical and economic sense simultaneously. Despite these advantages, home infusion claims face frequent denials, and patients often do not realize that the clinical and legal arguments for reversal are strong. This guide explains why home infusion claims are denied and how to build a winning appeal.

Why Insurers Deny Home Infusion Therapy

Medical Necessity Determination — Facility-Based Infusion Required

The most common denial argument is that the patient's clinical condition requires facility-based infusion rather than home infusion — typically because the insurer argues the patient is too medically complex for a home setting, requires real-time clinical monitoring, or has a risk profile that makes home infusion unsafe. Your appeal must directly address these arguments by documenting your treating physician's assessment of home infusion safety and the clinical supports in place (infusion nursing visits, emergency protocols, 24-hour pharmacy access). The Infusion Nurses Society (INS) 2021 Infusion Therapy Standards of Practice provide the authoritative clinical framework for home infusion safety standards.

"Site of Care" Redirection to Lower-Cost Facilities

A growing category of home infusion denial involves "site of care" policies: the insurer does not deny the infusion itself but argues that it should be performed at a hospital outpatient infusion center or physician office rather than at home. While site-of-care management is a legitimate insurer cost-management tool, it must be applied consistently and cannot override clinical necessity. If your treating physician has documented clinical reasons why home infusion is specifically necessary — including transportation burden, infection risk, or medical fragility — those factors are central to your appeal.

Prior Authorization Denied: How to Appeal" class="auto-link">Prior Authorization Missing or Documentation Insufficient

Home infusion consistently requires prior authorization, and denial frequently occurs because authorization was not obtained before service initiation or because the documentation submitted with the authorization request did not satisfy the insurer's specific clinical criteria. Common documentation gaps include: lack of physician attestation of home infusion safety, absence of the home infusion company's qualification documentation, or missing diagnosis codes that the insurer requires to tie the medication to a covered indication.

IVIG Denied for Off-Label Indications

Intravenous immunoglobulin (IVIG) is one of the most common home infusion medications, used for primary immunodeficiency disorders (ICD-10: D83.9), chronic inflammatory demyelinating polyneuropathy (CIDP, G61.81), myasthenia gravis (G70.01), dermatomyositis (M33.00), and other conditions. For CIDP and other neuromuscular indications, IVIG is FDA-approved (Gamunex-C, Privigen, and Hizentra for CIDP specifically). Denials for IVIG are particularly common when the indication is not an approved labeled use, or when the insurer applies restrictive step therapy requirements.

How to Appeal

Step 1: Request the Clinical Policy Bulletin and Specific Denial Criteria

Request the insurer's clinical policy bulletin governing home infusion therapy and the specific criteria applied to your claim. Many insurers have separate policies for IVIG, biologic infusions, and antibiotic infusions. Knowing which criteria apply to your specific medication allows you to construct a targeted response. For IVIG, identify the FDA-approved indication and whether your diagnosis falls within a covered indication under the policy.

Step 2: Obtain a Letter of Medical Necessity From Your Prescribing Physician

Your prescribing physician should provide a detailed letter explaining why the patient requires home infusion and why alternative delivery settings are not appropriate. The letter should cite the relevant ICD-10 diagnosis code (e.g., G61.81 for CIDP, D83.9 for primary immunodeficiency, M05.x for RA requiring biologic infusion), reference the FDA-approved indication for the medication if applicable, and explain why the home setting is clinically appropriate for this specific patient.

Step 3: Document the Clinical Safety Basis for Home Infusion

Address the insurer's safety concerns directly. Describe the home infusion nursing protocol — the frequency of nursing visits, the infusion company's clinical oversight structure, the emergency protocol in place, and the patient's or caregiver's training. Reference the INS 2021 Infusion Therapy Standards of Practice, which define clinical competency and safety standards for home infusion that are equivalent in many respects to facility-based administration.

Step 4: Demonstrate Cost-Effectiveness Where Applicable

For site-of-care denials, your appeal can include an economic argument. Home infusion for conditions such as CIDP, primary immunodeficiency, and antibiotic therapy for osteomyelitis is consistently less costly than hospital outpatient infusion center administration — typically by 40–60% according to NHIA data. If the insurer is denying home infusion in favor of a more expensive facility-based setting, this cost inversion is an argument against the denial's economic rationale.

Step 5: Address Medicare Coverage for Medicare Patients

If you are a Medicare beneficiary, Medicare Part B covers home infusion drugs under the 21st Century Cures Act home infusion benefit, which took effect January 1, 2021. This benefit covers professional services (nursing and other skilled services) associated with home infusion therapy. Medicare Advantage plans must cover the same home infusion benefits as traditional Medicare. If your Medicare or Medicare Advantage plan denied a home infusion claim, verify whether the denial is a coverage determination or a billing/coding issue — many Medicare home infusion denials are administrative in nature.

Step 6: Request External Independent Review: Complete Guide" class="auto-link">External Review and File a Complaint if Needed

If the internal appeal is denied, request external review by an IRO. For Medicare Part B home infusion denials, the appeal process runs through the CMS Medicare appeals system: Redetermination (Level 1), Reconsideration by a Qualified Independent Contractor (Level 2), and ALJ hearing (Level 3). For commercial plan denials, request state external review under the ACA and file a complaint with your state insurance commissioner if the denial criteria appear inconsistent with applicable law.

What to Include in Your Appeal

• Relevant ICD-10 diagnosis codes and CPT/HCPCS codes for the specific infusion medication (e.g., J1569 for IVIG, J0129 for abatacept, J9999 for other biologics)
• Your prescribing physician's letter documenting medical necessity and the clinical basis for home delivery
• Documentation of the home infusion company's clinical safety protocols and nursing oversight
• FDA approval status for the medication and indication, or peer-reviewed evidence supporting the indication if off-label
• For site-of-care denials, cost comparison data demonstrating that home infusion is less expensive than the alternative the insurer is proposing

Fight Back With ClaimBack

Home infusion denials often combine medical necessity arguments with site-of-care disputes, and each requires a different evidentiary response. ClaimBack helps you build an appeal that addresses all the relevant clinical and economic arguments with the documentation specificity insurers require to reverse these denials. ClaimBack generates a professional appeal letter in 3 minutes.

Start your free claim analysis →

Free analysis · No credit card required · Takes 3 minutes

Related Reading

• How to Write an Insurance Appeal Letter
• What Is Medical Necessity?
• Internal vs External Insurance Appeal